Choose Your Country or Region

Cilengitide trifluoroacetate

Name: Cilengitide trifluoroacetate
Brand: Selleck Chemicals
SKU: S7077
Rating: 5 (60 reviews)

Catalog No.S7077 Synonyms: EMD 121974, NSC 707544

For research use only.

Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Selleck's Cilengitide trifluoroacetate has been cited by 60 publications

Purity & Quality Control

Choose Selective Integrin Inhibitors

Related Compound Libraries

Biological Activity

Description

Targets

αvβ3 receptor ^[1] (Cell-free assay)	αvβ5 receptor ^[2] (Cell-free assay)
4.1 nM	79 nM

In vitro

Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. ^[1] Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and ﬁbrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively. ^[2] Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. ^[3] 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. ^[4] Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

G28	NVvROppoTnWwY4Tpc44hSXO\|YYm=	NX3hWmI6PTBizsznM41t	NUDvRY1{OzBxNkCvNVIxKG2rbh?=		MVnpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gSmFMNCCVcnOgZY5lKEGtdB?=	M1[yUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
HMEC-1	MYrGeY5kfGmxbjDBd5NigQ>?	MVSyNE81OC94MDFOwIcwdWx?			M3fxUIlvcGmkaYTzJGZCUyCjbnSgV5JkyqB?	NFTyNnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G44	MX7BdI9xfG:\|aYOgRZN{[Xl?	NYnEdlV3OS93L{WwJO69\y:vbB?=	NGW1WHczPCCq		NFrIcIJqdmS3Y3XzJIFxd3C2b4Ppdy=>	Mn3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
G28	NGnaSIlCeG:ydH;zbZMhSXO\|YYm=	NVTOUHZkOS93L{WwJO69\y:vbB?=	Ml3ENlQhcA>?		NEXpTJpqdmS3Y3XzJIFxd3C2b4Ppdy=>	Mof4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
G44	NVSwXmFwWHKxbHnm[ZJifGmxbjDBd5NigQ>?	NIn5fWQyNzVxNUCg{txoN22u	M4XuOlI1NzR6L{eyJIg>		MXHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
G28	NYjYVFVrWHKxbHnm[ZJifGmxbjDBd5NigQ>?	MnLaNU82NzVyIN88[{9udA>?	NGjWNGkzPC92OD:3NkBp		M3fwUIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NFLYTXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
HMEC-1	MUPBdI9xfG:\|aYOgRZN{[Xl?	NWPEbnZtOS93L{WwJO69\y:vbB?=	NHvCfHczPCCq		NHr2d21qdmS3Y3XzJIFxd3C2b4Ppdy=>	MkDwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
HMEC-1	MojNVJJwdGmoZYLheIlwdiCDc4PhfS=>	NVHuc3JFOS93L{WwJO69\y:vbB?=	M{DhdVI1NzR6L{eyJIg>		MnLqbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
HMEC-1	MnP3SpVv[3Srb36gRZN{[Xl?	M2PBb\|EwPS93MDFOwIcwdWx?	M2nGXFI1KGh?		MUjpcoR2[2W\|IHGg[I9{\SCmZYDlcoRmdnRiZHX0ZYNpdWWwdNMg	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
LNT-229	NX24b\|dVTnWwY4Tpc44hSXO\|YYm=	NEX4OIUxNjFxMT:xNEDPxE1?	NVvCclByOjRiaB?=		MkLxbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO\|E9N2F-
T98G	M4PjbWZ2dmO2aX;uJGF{e2G7	MYGwMlEwOS9zMDFOwG0>	NHnn[2QzPCCq		M1;IUolueGGrcoOgeIhmKGGmaHXzbY9vKG:oIHPlcIx{KHSxII\peJJwdmWldHnuJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NH7OSpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVE4OSd-MUmyNlEyPzF:L3G+
LN-18	NXfWUog5TnWwY4Tpc44hSXO\|YYm=	M{i4XFAvOS9zL{GwJO69VQ>?	MoXpNlQhcA>?		NHfGXHhqdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	Mle3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO\|EoRjF7MkKxNVcyRC:jPh?=
LN-308	MoTDSpVv[3Srb36gRZN{[Xl?	M4XJOlAvOS9zL{GwJO69VQ>?	MYOyOEBp		NXvHZnVHcW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NUHZNW5LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNlEyPzFpPkG5NlIyOTdzPD;hQi=>
U87MG	MnfRSpVv[3Srb36gRZN{[Xl?	M4S0elAvOS9zL{GwJO69VQ>?	NEK2foQzPCCq		M{PnTYlueGGrcoOgeIhmKGGmaHXzbY9vKG:oIHPlcIx{KHSxII\peJJwdmWldHnuJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	M3fqTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKxNVcyLz5zOUKyNVE4OTxxYU6=
U87	MVnGeY5kfGmxbjDBd5NigQ>?	MWOwMVI2KM7:Zz;tUC=>	NYTHOWRTOTJiaNMg		NHXLeXJqdmS3Y3XzJIF2fG:yaHHnfUBld3OnIHTldIVv\GWwdHz5	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd6OEO0N{c,OjF5OEizOFM9N2F-
U251	M1HxfWZ2dmO2aX;uJGF{e2G7	M3\aOFAuOjVizsznM41N	NHm0NG8yOiCqwrC=		M1HrbIlv\HWlZYOgZZV1d3CqYXf5JIRwe2ViZHXw[Y5l\W62bIm=	M37pT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U87	M2e0S2Fxd3C2b4Ppd{BCe3OjeR?=	MkDRNlUh\|rypL33M	NEnUZYYzPC92ODDo		MV\pcoR2[2W\|IHHwc5B1d3OrczDheEA1QCCqIIPp[45q\mmlYX70cJk>	MmDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OEizOFMoRjJzN{i4N\|Q{RC:jPh?=
U251	NYXFeFE6SXCxcITvd4l{KEG\|c3H5	M1vSOFI2KM7:Zz;tUC=>	MWSyOE81QCCq		MULpcoR2[2W\|IHHwc5B1d3OrczDheEA1QCCqIIPp[45q\mmlYX70cJk>	M4jxS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U87	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXOwMVI2KM7:Zz;tUC=>	MYewMVQ5KGh?		NWT4SHJvcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NWWxNXNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO\|g5OzR\|PD;hQi=>
U251	NV3ve4g3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6wMVI2KM7:Zz;tUC=>	MYKwMVQ5KGh?		NWTRUZBzcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd6OEO0N{c,OjF5OEizOFM9N2F-
U251MG	Mn7lRZBweHSxc3nzJGF{e2G7	NHnvbIUyKML3TR?=	M2[5VFQ5KGh?		MkPHbY5lfWOnczDhdI9xfG:\|aYO=	NV75e4ZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVQ5ODdpPkKzN\|U1QDB5PD;hQi=>
U87MG	NWrLeolPSXCxcITvd4l{KEG\|c3H5	NI\5cI8yKML3TR?=	NELyZoo1QCCq		M325PYlv\HWlZYOgZZBweHSxc3nz	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3NEiwO{c,OjN\|NUS4NFc9N2F-
U251MG	M3q4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfFXFBmOC1{NTFOwG0>	MW[yOE81QCCq		MVLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	M1PlO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
U87MG	NHrNdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W0ZVAuOjVizszN	M3nuV\|I1NzR6IHi=		NWLHWXBmcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	M17nfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
MCF-7	NYrVfVhMSXCxcITvd4l{KEG\|c3H5	M1O1TlAuOjBizszN	NVHvcnZyPDhiaB?=		M4jubolv\HWlZYOgZZBweHSxc3nz	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF3M{GwNkc,OjRzNUOxNFI9N2F-
T-47D	MXjBdI9xfG:\|aYOgRZN{[Xl?	M2XWclAuOjBizszN	MoTWOFghcA>?		MXHpcoR2[2W\|IHHwc5B1d3Orcx?=	NVzsWJh6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
MCF-7	NGXjRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInXO2QxNTJyIN88US=>	NXfScFVoQTZiaB?=		M4nyUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF3M{GwNkc,OjRzNUOxNFI9N2F-
T-47D	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2wMVIxKM7:TR?=	MYO5OkBp		MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NWXZZ5VyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVMyODJpPkK0NVU{OTB{PD;hQi=>
FaDu	M13qemFxd3C2b4Ppd{BCe3OjeR?=	NITIT5kzPcLiwsXNxsA>	NVjjS497PDkEoHlCpC=>		NU[4eWhocW6mdXPld{BieG:ydH;zbZM>	NYDheYN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
CAL27	NXzXd5RvSXCxcITvd4l{KEG\|c3H5	NGXGPWIzPcLiwsXNxsA>	MUG0POKhcMLi		MXrpcoR2[2W\|IHHwc5B1d3Orcx?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
SCC25	M{HKS2Fxd3C2b4Ppd{BCe3OjeR?=	M{jhZlI2yqEEtV5CpC=>	MonqOFjDqGkEoB?=		M4S2Wolv\HWlZYOgZZBweHSxc3nz	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
FaDu	M3;KdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXu2MlI26oDVMkCwxsDDvU1?	M2XT[\|czKGh?		MkXudoV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
CAL27	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDDUJY3NjJ34pETNlAxyqEEtV2=	NG\Vflk4OiCq		MoG4doV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3N{C1Okc,OjR3NUewOVY9N2F-
SCC25	NILJb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\ZdXV1Pi5{NfMAl\|IxOMLiwsXN	NEO3d5E4OiCq		M2n2WJJme3WudIOgcY9l\XKjdHWsJIRwe2VvZHXw[Y5l\W62IHfyc5d1cCCrbnjpZol1cW:w	NUDVSHFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
H28	Mlm4R4VtdCCYaXHibYxqfHliQYPzZZk>	MlnkNUBvVS1{MECg{txO	M1\NUFczKGh?		MYTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NVf4RWRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PVUzPzRpPkK0OVk2Ojd2PD;hQi=>
MM05	NHjxd4tE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVTXWoFMOSCwTT2yNFAh\|ryP	M2rvb\|czKGh?		NX22ZVVr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NEjpeo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
MSTO-211H	NFnMcplE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEjtVpUyKG6PLUKwNEDPxE1?	MnHIO\|IhcA>?		MWDk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NIr3O2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW5OVI4PCd-MkS1PVUzPzR:L3G+
REN	MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFLkNocyKG6PLUKwNEDPxE1?	NFH3fo44OiCq		NGPKd\|Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7NUK3OEc,OjR3OUWyO\|Q9N2F-
LN-308	NHu4NXpHfW6ldHnvckBCe3OjeR?=	MW[xNQKBkc7:bR?=	NFHUcnAzPCCq	NVG5fJB2TE2VT9Mg	MU\y[YR2[2W\|IFHoVkBxem:2ZXnuJIxmfmWuczDhcoQhTFKHIILldI9zfGW{IHHjeIl3cXS7	M1Kx[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUCwNFU3Lz5{NkWwNFA2PjxxYU6=
HaCaT	Mn\QSpVv[3Srb36gRZN{[Xl?	M{PFc\|Ex6oDLzszt	NXPtR4hJPDhiaB?=	NETLR\|NFVVORwrC=	MnX5doVlfWOnczDUS2Yu\|rJ{wrDtVm5CKGW6cILld5Nqd25?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVyMEC1Okc,OjZ3MECwOVY9N2F-
S-24	NH;RSopHfW6ldHnvckBCe3OjeR?=	NVy0cGlMOS9zMPMAje69dQ>?	NELFVWszPCCq	MmPoSG1UV8Li	MUDy[YR2[2W\|IFTSSUBz\XCxcoTldkBi[3Srdnn0fS=>	NUWw[WwyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
ZH-161	NIXFe2hHfW6ldHnvckBCe3OjeR?=	MWKxM\|Ex6oDLzszt	M2LvcVI1KGh?	MoLGSG1UV8Li	M1foUJJm\HWlZYOgSHJGKHKncH;yeIVzKGGldHn2bZR6	NWOzWm9WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
LN-308	NVrifYM4TnWwY4Tpc44hSXO\|YYm=	MorENU8yOC9zMEFihKnPxG1?	Ml;FNlQhcA>?	NH6yPVdFVVORwrC=	MV3y[YR2[2W\|IFTSSUBz\XCxcoTldkBi[3Srdnn0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=>	NH\6fmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWwNFA2Pid-Mk[1NFAxPTZ:L3G+
M21	NYPUS5l3TnWwY4Tpc44h[XO\|YYm=		NILkR2QyKGi{		NHnuSZBDcW6maX7nJIFn\mmwaYT5JJRwKGmwdHXndolvKGGucHjhek9j\XSjMzDo[ZRmem:maX3ldkBqdiCqdX3hckBOOjFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBqdnSnZ4Lpck1u\WSrYYTl[EBpfW2jbjDNNlEh[2WubDDh[Ihme2mxbjD0c{B3cXS{b37lZ5RqdiCjZoTldkAyKGi{IHnuJJBz\XOnbnPlJI9nKE2wQ3yyMEBKSzVyIE2gNE4xODB2IN88UU4>	NEXDe5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1N\|gyPCd-Mk[3OVM5OTR:L3G+
HEK293T	NWrEdIlbTnWwY4Tpc44h[XO\|YYm=		M4C2[\|IhcHK\|		NWn5e45bSmmwZHnu[{Bi\m[rbnn0fUB1dyC\|b3z1ZoxmKHS{dX7jZZRm\CCqdX3hckBz\WOxbXLpcoFvfCCIYz30ZYdo\WRiYXzwbIFX[mW2YUOgZY5lKGmwdHXndolveyC5ZYLlJIV5eHKnc4Pl[EBqdiCKRVuyPVNVKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHPvcZBmfGm2aX;uJGVNUVODLXzpb4Uh[XO\|YYmsJGlEPTBiPTCwMlAxODVzIN88UU4>	NHPhZZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVA6Pid-MkSwPVUxQTZ:L3G+
HT-29	MWPGeY5kfGmxbjDhd5NigQ>?		NYPFTIhZOiCqcoO=		NV7hTot7SW62YXfvcol{fCCjY4Tpeol1gSCjdDDpcpRm\3KrbjDhcJBp[V[kZYThOUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKVD2yPUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBi\Ginc3nvckB1dyC4aYTyc45m[3SrbjDh[pRmeiB{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGyJO69VS5?	MkfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|NUG1PVQoRjJ6M{WxOVk1RC:jPh?=
HEK293	MlTMSpVv[3Srb36gZZN{[Xl?		MmLrNkBpenN?		NV\sOmM5SW62YXfvcol{fCCjY4Tpeol1gSCjdDDpcpRm\3KrbjDhcJBp[V[kZYThN{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwh[WSqZYPpc44hfG9iZnnidolvd2enbjDh[pRmeiB{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkKyJO69VS5?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MUW5OEc,Ojh\|NUG1PVQ9N2F-
SKOV3	NXm1copRTnWwY4Tpc44h[XO\|YYm=		NXXV[Id5OiCqcoO=		NFe2NYpCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHnueIVoemmwIHHsdIhiXmKndHGzZYxxcGGYYnX0ZVUhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU1vPWlMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwh[WSqZYPpc44hfG9iZnnidolvd2enbjDh[pRmeiB{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkO3JO69VS5?	M1LXPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WxOVk1Lz5{OEO1NVU6PDxxYU6=
U87MG	M2G4bGZ2dmO2aX;uJIF{e2G7	NGHEWY8yODBibl2=	M3HlT\|I1KGi{cx?=		NEHK[ZNKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJA2OyCjY3P1cZVt[XSrb36gZZQhOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG	NF\FfIpHfW6ldHnvckBie3OjeR?=	NWjSOm0{OTByIH7N	NXn3THRlOjRiaILz		MVzJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF\|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIC1N{Bi[2O3bYXsZZRqd25iYYSgNVAxKG6PIHHmeIVzKDJ2IHjyd{BqdiCycnXz[Y5k\SCxZjDNSG0zKGmwaHnibZRweiCwdYTsbY4uOyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k	MljhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	MV\GeY5kfGmxbjDhd5NigQ>?	MoXTNVAxKG6P	MmfZNlQhcHK\|		MlnhTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMh[WOldX31cIF1cW:wIHH0JFExOCCwTTDh[pRmeiB{NDDodpMhcW5icILld4Vv[2Vib3[gUWROOiCrbnjpZol1d3JiboX0cIlvNTNiYX7kJG1FVTRiaX7obYJqfG:{IGPKMVE4OjJ3NUCgZpkhX2W\|dHXyckBjdG:2IH3leIhw\A>?	M4rMW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N\|A{Lz5{OUe3OVMxOzxxYU6=
U87MG	MULGeY5kfGmxbjDhd5NigQ>?	M1jMZlExOCCwTR?=	MojDPEBpenN?		NYH6[oZpUW6qaXLpeIlwdiCxZjDhcJBp[V[kZYThN{BqdnSnZ4LpckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBOTE1{IH3SUmEh\XiycnXzd4lwdiCjdDCxNFAhdk1iYX\0[ZIhQCCqcoOgbY4heHKnc3XuZ4Uhd2ZiTVTNNkBqdmirYnn0c5IhdnW2bHnuMVMh[W6mIF3EUVQhcW6qaXLpeI9zKFOMLUG3NlI2PTBiYomgVnQuWEOUIH3leIhw\A>?	MkLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	M4noVWZ2dmO2aX;uJIF{e2G7	MVOxNFAhdk1?	NGHobHkzPCCqcoO=		MV\Jcohq[mm2aX;uJI9nKGGucHjhWoJmfGF\|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIGDVUWEhdVKQQTDlfJBz\XO\|aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiYomgVnQuWEOUIH3leIhw\A>?	M3nWTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N\|A{Lz5{OUe3OVMxOzxxYU6=
U87MG	NIPWeGdHfW6ldHnvckBie3OjeR?=	MV2xNFAhdk1?	NV[zVndoOjRiaILz		MVLJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF\|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIGDVUWEhdVKQQTDlfJBz\XO\|aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZpkhWlRvUFPSJI1mfGixZB?=	MlTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	NFnzUFlHfW6ldHnvckBie3OjeR?=	NYX1RWJ5OTByIH7N	M{SwbVI1KGi{cx?=		NF;CNHNKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgbY4heHKnc3XuZ4Uhd2ZiTVTNOEBqdmirYnn0c5IhW0pvMUeyNlU2OCCkeTDSWE1RS1JibXX0bI9l	M1LUN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N\|A{Lz5{OUe3OVMxOzxxYU6=
U87MG	M2rje2Z2dmO2aX;uJIF{e2G7	NFXzeXcyODBibl2=	NFTaZmIzPCCqcoO=		M13wNGlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gVHVOSSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDpckBxemW\|ZX7j[UBw\iCPRF2yJIlvcGmkaYTvdkBvfXSuaX6tN{BidmRiTVTNOEBqdmirYnn0c5IhW0pvMUeyNlU2OCCkeTDSWE1RS1JibXX0bI9l	NXLRbXlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	NEDtZpFHfW6ldHnvckBie3OjeR?=	MWCxNFAhdk1?	NV\sVYtFOjRiaILz		MVvJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF\|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIICyNUBuWk6DIHX4dJJme3Orb36gZZQhOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDSWE1RS1JibXX0bI9l	Mny2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	NWnRcWFXSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	MkLHNVAxKG6P	MVS3NkBpenN?		M3;aVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZZQhOTByIH7NJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDifUBOXFNiYYPzZZk>	M1vVZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N\|A{Lz5{OUe3OVMxOzxxYU6=
U87MG	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NXHw[HoxOTByIH7N	MkfUO\|IhcHK\|		NYjJS45mSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BifCBzMECgcm0h[W[2ZYKgO\|IhcHK\|IHnuJJBz\XOnbnPlJI9nKE2GTUKgbY5pcWKrdH;yJI52fGyrbj2zJIFv\CCPRF20JIlvcGmkaYTvdkBUUi1zN{KyOVUxKGK7IF3UV{Bie3OjeR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG	MWrD[YxtKGO7Y3zlJIF{e2G7	MmftNVAxKG6P	NWn4[ZVYOjRiaILz		NHXIcFdE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS\|EheGijc3WgZZQhOTByIH7NJIFnfGW{IEK0JIhzew>?	Mlz5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	M2nHdGFvfGlvaX72ZZNqfmViYYPzZZk>	NV\KdYFKOTBidV2=	MkfhNlQhcHK\|		MUTBcpRqNWmwdnHzbZZmKGGldHn2bZR6KGmwIHj1cYFvKFV6N13HJINmdGy\|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSC2cnHud5dmdGxiYYPzZZk>	NXnUbZQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	MnOwRY51cS2rbo\hd4l3\SCjc4PhfS=>	M2O4bFExKHWP	M{S3VVI1KGi{cx?=		MUDBcpRqNWmwdnHzbZZmKGGldHn2bZR6KGmwIHj1cYFvKFV6N13HJINmdGy\|IHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BqdiCycnXz[Y5k\SCxZjDNSG0zKGmwaHnibZRweiCwdYTsbY4uOyCjbnSgUWROPCCrbnjpZol1d3JiU1qtNVczOjV3MDDifUB1emGwc4flcIwh[XO\|YYm=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	pFAK / p-AKT ; GLI1	19114005 31366904
Immunofluorescence	VE-cadherin / β3 integrin	19212436
Growth inhibition assay	Cell number	24153102

In vivo

Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). ^[5] Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation. ^[6]

Protocol (from reference)

Kinase Assay:^[2]	Integrin-binding competition assay: Recombinant soluble integrins are immobilized, and peptides, which are serially diluted in Tris-buffered saline (TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl₂, 1 mM MgCl₂ 10 μM MnCl₂, 20 mM Tris-HCl; pH 7.4), are added in parallel with biotinylated vitronectin (to 1μg/mL). After a 3-h incubation at 37℃ and washing with Tris–buffered saline, bound ligand is detected by incubation with an antibiotin alkaline phosphatase-conjugated antibody (BioRad) followed by development with p-nitrophenyl phosphatase substrate. The reaction is stopped by the addition of NaOH and the color intensity read at 405 nm.
Cell Research:^[3]	Cell lines: Human microvascular endothelial cell line HMEC-1 Concentrations: 1-50 μg/mL Incubation Time: 3 days Method: HMEC-1 (1×10⁴ per well) are seeded on uncoated 48 well plates and incubated in medium containing 4% FCS with Cilengitide. After incubation for 72 hours at 37℃, cells are trypsinized and counted.
Animal Research:^[5]	Animal Models: Human glioblastoma xenografts U87 MG Dosages: 100μg Administration: Daily i.p.

References

+ Expand

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	702.68
Formula	C₂₉H₄₁F₃N₈O₉
CAS No.	199807-35-7
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N.C(=O)(C(F)(F)F)O

Download Cilengitide trifluoroacetate SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01517776	Terminated	Drug: Cilengitide\|Drug: Temozolomide	Gliomas	Martin-Luther-Universität Halle-Wittenberg\|Merck KGaA Darmstadt Germany	January 2012	Phase 2
NCT01118676	Completed	Drug: cilengitide radiochemotherapy	Locally Advanced Non Small Cell Lung Cancer (NSCLC)	Institut Claudius Regaud\|Merck KGaA Darmstadt Germany	March 2010	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-11-29)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?

Answer:
S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.

Question 2:
Is Cilengitide a TFA salt?

Answer:
S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):